EL7.AI
StocksMediumUpdated×3•Originally published 4 October 2026•Updated 5 October 2026•
1 min read

CSL Signs $1.6 Billion Rare Disease Drug Deal with Alentis

Key Facts

1Australia's CSL entered an agreement with Swiss-based Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases.
2The deal is valued at up to $1.6 billion before development funding is taken into account.

Australia's CSL entered an agreement with Swiss-based Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases. Reuters reported that the deal is valued at up to $1.6 billion before development funding is taken into account.

The partnership aims to expand CSL's portfolio in the rare disease sector by leveraging Alentis's therapeutic pipeline. This strategic move strengthens the company's position in specialized medicine, with the final deal value contingent on reaching specific development milestones.

Latest Updates · 2

  1. Notable·

    Update: CSL shares rose in trading following the announcement of the $1.6 billion deal. The price movement reflects investor optimism regarding the growth prospects provided by the partnership with Alentis in the specialized medicine sector.

  2. Notable·

    Update: The collaboration focuses on the experimental drug lixudebart, which is currently in Phase 2 clinical trials. The drug is being tested for the treatment of ANCA-associated vasculitis.